JP2015517309A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517309A5 JP2015517309A5 JP2015511761A JP2015511761A JP2015517309A5 JP 2015517309 A5 JP2015517309 A5 JP 2015517309A5 JP 2015511761 A JP2015511761 A JP 2015511761A JP 2015511761 A JP2015511761 A JP 2015511761A JP 2015517309 A5 JP2015517309 A5 JP 2015517309A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antibody
- multispecific antibody
- multispecific
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 30
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 13
- 210000001161 mammalian embryo Anatomy 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 238000012216 screening Methods 0.000 claims 8
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 6
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 6
- 210000002919 epithelial cell Anatomy 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 210000002950 fibroblast Anatomy 0.000 claims 4
- 210000003292 kidney cell Anatomy 0.000 claims 4
- 210000004180 plasmocyte Anatomy 0.000 claims 4
- 238000001243 protein synthesis Methods 0.000 claims 3
- 230000014616 translation Effects 0.000 claims 3
- 210000005253 yeast cell Anatomy 0.000 claims 3
- 241000282465 Canis Species 0.000 claims 2
- 241000282693 Cercopithecidae Species 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 2
- 241000289581 Macropus sp. Species 0.000 claims 2
- 241000699673 Mesocricetus auratus Species 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 2
- 210000002308 embryonic cell Anatomy 0.000 claims 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 230000007717 exclusion Effects 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000012004 kinetic exclusion assay Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- 241001436793 Meru Species 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645302P | 2012-05-10 | 2012-05-10 | |
| US61/645,302 | 2012-05-10 | ||
| PCT/US2013/040575 WO2013170168A1 (en) | 2012-05-10 | 2013-05-10 | Multi-specific monoclonal antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017246602A Division JP6465953B2 (ja) | 2012-05-10 | 2017-12-22 | 多重特異性モノクローナル抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517309A JP2015517309A (ja) | 2015-06-22 |
| JP2015517309A5 true JP2015517309A5 (enExample) | 2016-07-21 |
| JP6267689B2 JP6267689B2 (ja) | 2018-01-24 |
Family
ID=49551307
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511761A Active JP6267689B2 (ja) | 2012-05-10 | 2013-05-10 | 多重特異性モノクローナル抗体 |
| JP2017246602A Active JP6465953B2 (ja) | 2012-05-10 | 2017-12-22 | 多重特異性モノクローナル抗体 |
| JP2019000631A Active JP6723392B2 (ja) | 2012-05-10 | 2019-01-07 | 多重特異性モノクローナル抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017246602A Active JP6465953B2 (ja) | 2012-05-10 | 2017-12-22 | 多重特異性モノクローナル抗体 |
| JP2019000631A Active JP6723392B2 (ja) | 2012-05-10 | 2019-01-07 | 多重特異性モノクローナル抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9969813B2 (enExample) |
| EP (2) | EP2847231B1 (enExample) |
| JP (3) | JP6267689B2 (enExample) |
| KR (3) | KR101951641B1 (enExample) |
| CN (2) | CN108690132B (enExample) |
| AU (3) | AU2013259276B2 (enExample) |
| CA (3) | CA3051210A1 (enExample) |
| DK (1) | DK2847231T3 (enExample) |
| ES (1) | ES2749200T3 (enExample) |
| HK (1) | HK1210620A1 (enExample) |
| IN (1) | IN2014DN09417A (enExample) |
| MX (2) | MX362705B (enExample) |
| WO (1) | WO2013170168A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013259276B2 (en) | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| US9409139B2 (en) | 2013-08-05 | 2016-08-09 | Twist Bioscience Corporation | De novo synthesized gene libraries |
| CA2947605A1 (en) | 2014-05-13 | 2015-11-19 | Bioatla, Llc | Conditionally active biological proteins |
| US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| EP3186284B1 (en) | 2014-08-28 | 2022-04-06 | BioAtla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| CA2975852A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| AU2016324296A1 (en) * | 2015-09-18 | 2018-04-12 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
| CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
| EP3403098B1 (en) | 2016-01-12 | 2021-09-22 | BioAtla, Inc. | Diagnostics using conditionally active antibodies |
| US10697972B2 (en) | 2016-01-12 | 2020-06-30 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| JP7051715B2 (ja) | 2016-05-13 | 2022-04-11 | バイオアトラ、エルエルシー | 抗Ｒｏｒ２抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用 |
| CN110248724B (zh) | 2016-09-21 | 2022-11-18 | 特韦斯特生物科学公司 | 基于核酸的数据存储 |
| US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| WO2018156792A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| IL271205B2 (en) | 2017-06-12 | 2025-02-01 | Twist Bioscience Corp | Methods for assembling continuous nucleic acids |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| CN111356477B (zh) * | 2017-08-01 | 2024-08-30 | Ab工作室有限公司 | 双特异性抗体及其用途 |
| US11407837B2 (en) | 2017-09-11 | 2022-08-09 | Twist Bioscience Corporation | GPCR binding proteins and synthesis thereof |
| KR102637566B1 (ko) | 2017-10-20 | 2024-02-16 | 트위스트 바이오사이언스 코포레이션 | 폴리뉴클레오타이드 합성을 위한 가열된 나노웰 |
| WO2019122409A1 (en) | 2017-12-22 | 2019-06-27 | Argenx Bvba | Bispecific antigen binding construct |
| CN112041438B (zh) | 2018-01-04 | 2025-05-23 | 特韦斯特生物科学公司 | 基于dna的数字信息存储 |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US20210009711A1 (en) | 2018-03-14 | 2021-01-14 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| KR20210009421A (ko) * | 2018-06-14 | 2021-01-26 | 바이오아트라, 엘엘씨 | 다중 특이적 항체 구조체 |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN112566929A (zh) * | 2018-08-21 | 2021-03-26 | 生物蛋白有限公司 | 具pH选择性的条件活性蛋白质 |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CA3124980A1 (en) | 2018-12-26 | 2020-07-02 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| US12463463B2 (en) | 2019-01-28 | 2025-11-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| GB2598218B (en) | 2019-02-21 | 2024-05-08 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| EP3927747A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| CA3131016A1 (en) | 2019-02-21 | 2020-08-27 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020172598A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| CN113785057A (zh) | 2019-02-26 | 2021-12-10 | 特韦斯特生物科学公司 | 用于抗体优化的变异核酸文库 |
| KR20210143766A (ko) | 2019-02-26 | 2021-11-29 | 트위스트 바이오사이언스 코포레이션 | Glp1 수용체에 대한 변이체 핵산 라이브러리 |
| KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| JP2022550497A (ja) | 2019-06-21 | 2022-12-02 | ツイスト バイオサイエンス コーポレーション | バーコードに基づいた核酸配列アセンブリ |
| US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CA3155629A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for crth2 |
| AU2020355027A1 (en) | 2019-09-23 | 2022-04-21 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| WO2021084104A1 (en) | 2019-10-30 | 2021-05-06 | Bioinvent International Ab | Tetravalent antibody molecules |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| KR20230028242A (ko) | 2020-04-24 | 2023-02-28 | 마렝고 테라퓨틱스, 인크. | T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도 |
| GB2616354A (en) | 2020-08-26 | 2023-09-06 | Marengo Therapeutics Inc | Methods of detecting TRBC1 or TRBC2 |
| CA3190766A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3197047A1 (en) * | 2020-10-07 | 2022-04-14 | Amgen Inc. | Rational selection of building blocks for the assembly of multispecific antibodies |
| KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
| WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
| EP4402121A1 (en) | 2021-09-14 | 2024-07-24 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
| EP4402123A1 (en) | 2021-09-14 | 2024-07-24 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
| EP4452928A1 (en) | 2021-12-23 | 2024-10-30 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
| CA3255619A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Man Inc | CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5677149A (en) | 1992-11-24 | 1997-10-14 | G.D. Searle & Co., | Interleukin-3 (IL-3) mutant polypeptides and their recombinant production |
| GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| AU680685B2 (en) | 1993-09-22 | 1997-08-07 | Medical Research Council | Retargeting antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| EP0954340B1 (en) | 1996-05-03 | 2007-06-27 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer |
| US7011812B1 (en) | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| AU765003B2 (en) | 1998-03-27 | 2003-09-04 | Genentech Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
| US7833528B2 (en) | 1998-06-22 | 2010-11-16 | Immunomedics, Inc. | Use of multispecific, non-covalent complexes for targeted delivery of therapeutics |
| WO2001097855A2 (en) | 2000-06-20 | 2001-12-27 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
| US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| ATE391174T1 (de) | 2000-10-20 | 2008-04-15 | Chugai Pharmaceutical Co Ltd | Modifizierter tpo-agonisten antikörper |
| WO2002064746A2 (en) | 2001-02-14 | 2002-08-22 | Uab Research Foundation | Combined transductional and transcriptional targeting system for improved gene delivery |
| AU2002233340B2 (en) | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| US20050142539A1 (en) * | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
| EP1505148B1 (en) | 2002-04-26 | 2009-04-15 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening for agonistic antibodies |
| AU2013200009B2 (en) * | 2002-07-18 | 2015-05-07 | Merus N.V. | Recombinant production of mixtures of antibodies |
| SI1523496T1 (sl) * | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| WO2004065611A1 (ja) | 2003-01-21 | 2004-08-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体の軽鎖スクリーニング方法 |
| US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
| US20090191213A9 (en) | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| EP1631315B1 (en) * | 2003-09-24 | 2014-07-30 | Millennium Pharmaceuticals, Inc. | Antibodies which bind human cxcr3 |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| US20050266425A1 (en) * | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| US8420783B2 (en) | 2004-12-08 | 2013-04-16 | Immunomedics, Inc. | Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| AU2006204459B2 (en) | 2005-01-05 | 2012-11-01 | F-Star Therapeutics Limited | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| CA2623517A1 (en) | 2005-09-23 | 2007-04-05 | Walter Reed Army Institute Of Research (Wrair) | Antibodies with simultaneous subsite specificities to protein and lipid epitopes |
| MY159375A (en) | 2006-03-21 | 2016-12-30 | Genentech Inc | Combinatorial therapy |
| ES2399075T3 (es) | 2006-08-30 | 2013-03-25 | Genentech, Inc. | Anticuerpos multiespecíficos |
| GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| BRPI0813645A2 (pt) * | 2007-06-25 | 2014-12-30 | Esbatech Alcon Biomed Res Unit | Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas |
| EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
| CN101842116A (zh) * | 2007-08-28 | 2010-09-22 | 比奥根艾迪克Ma公司 | 结合igf-1r多个表位的组合物 |
| WO2009042746A1 (en) | 2007-09-26 | 2009-04-02 | Genentech, Inc. | Novel antibodies |
| EP2113255A1 (en) * | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| MX345039B (es) | 2008-06-25 | 2017-01-16 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles que inhiben el tnfa. |
| US8632774B2 (en) | 2008-07-02 | 2014-01-21 | Emergent Product Development Seattle, Llc | Antagonists of IL-6 |
| US20110152173A1 (en) | 2008-07-02 | 2011-06-23 | Emergent Product Development Seattle ,LLC | TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS |
| US20110177070A1 (en) | 2008-07-02 | 2011-07-21 | Emergent Product Development Seatlle, LLC | TGF-Beta Antagonist Multi-Target Binding Proteins |
| WO2010008690A1 (en) * | 2008-07-14 | 2010-01-21 | Uchicago Argonne, Llc | Methods for systematic control of protein stability |
| US20110158995A1 (en) | 2008-07-28 | 2011-06-30 | Renault S.A.S | Multi-Specific Binding Proteins Targeting B Cell Disorders |
| HRP20180045T1 (hr) | 2008-10-02 | 2018-03-23 | Aptevo Research And Development Llc | Proteini antagonisti cd86 koji se vežu na više meta |
| CN102356092B (zh) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| KR101508043B1 (ko) | 2009-09-29 | 2015-04-06 | 로슈 글리카트 아게 | 이중특이적 사멸 수용체 아고니스트성 항체 |
| KR20120093312A (ko) | 2009-10-30 | 2012-08-22 | 바이엘 헬스케어 엘엘씨 | 항체 모방체 스캐폴드 |
| JP6184695B2 (ja) | 2009-12-04 | 2017-08-23 | ジェネンテック， インコーポレイテッド | 多重特異性抗体、抗体アナログ、組成物、及び方法 |
| EP2519544A1 (en) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
| SMT201900372T1 (it) * | 2010-02-08 | 2019-09-09 | Regeneron Pharma | Topo con catena leggera comune |
| WO2011109726A2 (en) * | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| DK2560683T4 (da) * | 2010-04-23 | 2022-08-29 | Hoffmann La Roche | Fremstilling af heteromultimeriske proteiner |
| ES2966088T3 (es) | 2010-07-16 | 2024-04-18 | Bioatla Inc | Nuevos métodos de evolución de proteínas |
| EP2606064B1 (en) | 2010-08-16 | 2015-02-25 | NovImmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| TR201802772T4 (tr) | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül. |
| CN103384682B (zh) | 2011-01-14 | 2017-04-12 | Ucb医药有限公司 | 结合il‑17a和il‑17f的抗体分子 |
| EP2500073A1 (en) | 2011-03-17 | 2012-09-19 | ChromaCon AG | Method for identification and purification of multi-specific polypeptides |
| EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| WO2013003652A1 (en) | 2011-06-28 | 2013-01-03 | Sea Lane Biotechnologies, Llc | Multispecific stacked variable domain binding proteins |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| EP2543680A1 (en) | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| WO2013049254A1 (en) | 2011-09-26 | 2013-04-04 | Jn Biosciences Llc | Hybrid constant regions |
| SG11201405468QA (en) | 2012-03-14 | 2014-10-30 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| WO2013142255A2 (en) | 2012-03-22 | 2013-09-26 | University Of Miami | Multi-specific binding agents |
| AU2013259276B2 (en) * | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| JP2015520168A (ja) | 2012-05-24 | 2015-07-16 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 多重特異性抗体 |
| EP2880057A4 (en) | 2012-08-02 | 2016-03-23 | Jn Biosciences Llc | MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL |
| KR20140036905A (ko) | 2012-09-18 | 2014-03-26 | 삼성전자주식회사 | 이중특이 항체를 포함하는 단백질 복합체 |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
-
2013
- 2013-05-10 AU AU2013259276A patent/AU2013259276B2/en active Active
- 2013-05-10 CN CN201810258801.6A patent/CN108690132B/zh active Active
- 2013-05-10 KR KR1020147033427A patent/KR101951641B1/ko active Active
- 2013-05-10 JP JP2015511761A patent/JP6267689B2/ja active Active
- 2013-05-10 MX MX2014013590A patent/MX362705B/es active IP Right Grant
- 2013-05-10 MX MX2019001355A patent/MX2019001355A/es unknown
- 2013-05-10 US US14/399,617 patent/US9969813B2/en active Active
- 2013-05-10 EP EP13788439.1A patent/EP2847231B1/en active Active
- 2013-05-10 KR KR1020197017228A patent/KR102089526B1/ko active Active
- 2013-05-10 IN IN9417DEN2014 patent/IN2014DN09417A/en unknown
- 2013-05-10 EP EP19174963.9A patent/EP3553089A1/en active Pending
- 2013-05-10 HK HK15108289.6A patent/HK1210620A1/xx unknown
- 2013-05-10 CN CN201380035170.7A patent/CN104583239B/zh active Active
- 2013-05-10 DK DK13788439.1T patent/DK2847231T3/da active
- 2013-05-10 CA CA3051210A patent/CA3051210A1/en active Pending
- 2013-05-10 KR KR1020197004783A patent/KR102023401B1/ko active Active
- 2013-05-10 WO PCT/US2013/040575 patent/WO2013170168A1/en not_active Ceased
- 2013-05-10 ES ES13788439T patent/ES2749200T3/es active Active
- 2013-05-10 CA CA3202536A patent/CA3202536A1/en active Pending
- 2013-05-10 CA CA2872908A patent/CA2872908C/en active Active
-
2017
- 2017-12-22 JP JP2017246602A patent/JP6465953B2/ja active Active
-
2018
- 2018-02-16 AU AU2018201159A patent/AU2018201159B2/en active Active
- 2018-03-23 US US15/934,596 patent/US20180237543A1/en not_active Abandoned
-
2019
- 2019-01-07 JP JP2019000631A patent/JP6723392B2/ja active Active
- 2019-01-31 US US16/264,028 patent/US10696750B2/en active Active
-
2020
- 2020-03-25 AU AU2020202133A patent/AU2020202133B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517309A5 (enExample) | ||
| ES2564635T3 (es) | Anticuerpos anti-IL-6/IL-6R y métodos de uso de los mismos | |
| US12441803B2 (en) | Engineered CD25 polypeptides and uses thereof | |
| JP2009153527A5 (enExample) | ||
| PE20200862A1 (es) | Anticuerpos anti-trem2 y metodos relacionados | |
| FI3571224T3 (fi) | Parannettuja seerumialbumiinin sitojia | |
| EA201792584A1 (ru) | Моноклональное антитело к pd-1 и способ его получения | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| HK1245300A1 (zh) | 靶组织特异性抗原结合分子 | |
| ECSP20039728A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos | |
| EA201992670A1 (ru) | Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител | |
| PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
| JP2019500007A5 (enExample) | ||
| RU2013102596A (ru) | МЫШИ, ЭКСПРЕССИРУЮЩИЕ ЛЕГКУЮ ЦЕПЬ С ВАРМАБЕЛЬНОЙ ОБЛАСТЬЮ α-ЧЕЛОВЕКА И КОНСТАНТНОЙ ОБЛАСТЬЮ МЫШИ | |
| JP2014516540A5 (enExample) | ||
| JP2017522888A5 (enExample) | ||
| KR20170070070A (ko) | Vh-vl-도메인간 각도 기반 항체 인간화 | |
| JP2015519055A5 (enExample) | ||
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| EA201890447A1 (ru) | Гуманизированные антитела к рецептору ccr7 | |
| JP7054209B2 (ja) | エピトープ均質化抗体パネル、ならびにその作製方法および利用 | |
| CN111320693A (zh) | 抗EphA4抗体 | |
| EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
| JP2015526071A (ja) | ヒトＧｎＲＨ受容体に対するモノクローナル抗体のヒト化形態 | |
| WO2015110114A3 (de) | Hybridom-zelllinie (my-c-cc0c2-259-1 a4) und deren verwendung zur herstellung eines monoklonalen antikörpers gegen das humane, herzspezifische myosin binding protein c (c-protein, mybpc3, cmybp-c oder my-c) |